STING1 and breast carcinoma: The synthetic CDNs, 2′3′-c-di-AM(PS)2 (ADU-S100, also called MIW815 or RR-CDA) and 3′3′-cGAMP (cGAMP) and GSK532, and CDN-unrelated STING agonists, TTI-10001 and CRD5500 (also called LB-061), activate human STING alleles and have exhibited antitumour efficacy when administered intratumourally in several mouse tumour models including CT26 colon [53,156,157], MC-38 colon [158], Lewis lung carcinoma [52], and 4T1 breast carcinomas [159].